Drug Trial Radar · NCT06932263
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Mar 26, 2025
Primary completion
Jun 7, 2027
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
Conditions
- Asthma
Interventions
TozorakimabDrug
The drug will be administered subcutaneously.
PlaceboDrug
Placebo will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualised rate of severe asthma exacerbationsTime frame: Over 26 to 52 weeks
Locations
223 sites in 21 countries. Site status is shown where the registry gives one.
Research Site
Bakersfield, California · Recruiting
Research Site
Huntington Beach, California · Withdrawn
Research Site
La Mesa, California · Terminated
Research Site
Loma Linda, California · Withdrawn
Research Site
Long Beach, California · Recruiting
Research Site
Newport Beach, California · Recruiting
Research Site
San Jose, California · Recruiting
Research Site
Wilmington, Delaware · Terminated
Research Site
Cutler Bay, Florida · Suspended
Research Site
Hialeah, Florida · Suspended
Research Site
Leesburg, Florida · Withdrawn
Research Site
Miami, Florida · Suspended
Research Site
Miami, Florida · Suspended
Research Site
Miami Lakes, Florida · Suspended
Research Site
Orlando, Florida · Suspended
Research Site
Palmetto Bay, Florida · Suspended
Research Site
Tampa, Florida · Suspended
Research Site
Winter Park, Florida · Suspended
Research Site
Boise, Idaho · Withdrawn
Research Site
Noblesville, Indiana · Recruiting
Research Site
West Des Moines, Iowa · Terminated
Research Site
Hutchinson, Kansas · Recruiting
Research Site
Kansas City, Kansas · Withdrawn
Research Site
Louisville, Kentucky · Recruiting
Research Site
White Marsh, Maryland · Withdrawn
Research Site
Worcester, Massachusetts · Recruiting
Research Site
Farmington Hills, Michigan · Recruiting
Research Site
Warren, Michigan · Withdrawn
Research Site
St Louis, Missouri · Withdrawn
Research Site
Bellevue, Nebraska · Withdrawn
Research Site
Grand Island, Nebraska · Recruiting
Research Site
Omaha, Nebraska · Recruiting
Research Site
Millville, New Jersey · Not yet recruiting
Research Site
Mullica Hill, New Jersey · Recruiting
Research Site
Toms River, New Jersey · Recruiting
Research Site
Horseheads, New York · Recruiting
Research Site
Maspeth, New York · Recruiting
Research Site
Asheville, North Carolina · Withdrawn
Research Site
Huntersville, North Carolina · Withdrawn
Research Site
Kings Mountain, North Carolina · Recruiting
Showing 40 of 223 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.